Reduced-dose RT with Cisplatin improves outcomes for HPV-associated oropharyngeal carcinoma

January 29, 2021

A combination of reduced-dose radiotherapy using intensity-modulated radiotherapy (IMRT) combined with concurrent cisplatin met the threshold for disease control and quality of life compared to the standard of care for good-risk patients with HPV-associated oropharyngeal squamous cell carcinoma on the NRG Oncology clinical trial NRG-HN002. The outcomes from this data justify the advancement of the reduced radiotherapy dose with cisplatin to a Phase III clinical trial setting in this population. These results were recently published in the Journal of Clinical Oncology.

"Currently, patients with HPV-associated oropharyngeal cancer are treated with 70 Gy of radiotherapy with concurrent platinum chemotherapy, but this treatment is typically associated with severe short-and long-term toxicities. NRG-HN002 was designed as a Phase II trial assessing a treatment approach using a reduced radiotherapy dose with or without cisplatin based on preclinical data and data from single-arm studies to see if this produced good outcomes for this patient population," stated Sue S. Yom, MD, of the University of California, San Francisco, and the lead author of the NRG-HN002 manuscript.

NRG-HN002 randomly assigned 306 eligible patients to either the experimental arm of 60 Gy of IMRT for 6 weeks with concurrent weekly cisplatin (IMRT+C) or the control arm of 60 Gy of IMRT for five weeks. In order to establish acceptability as compared to the standard of care, at least one arm had to achieve a 2-year progression-free survival (PFS) rate above the historical control rate of 85% as well as a 1-year mean composite score of 60 or greater based on the MD Anderson Dysphagia Inventory (MDADI).

Data indicated that the IMRT+C arm yielded a 2-year PFS rate of 90.5% (p=0.04, rejecting the null hypothesis of 2-year PFS ? 85%) compared to 87.3% (p=0.23) in the IMRT alone arm. 1-year mean MDADI scores were 85.30 for the IMRT+C arm versus 81.76 for the IMRT alone arm. 2-year overall survival rates were 96.7% and 97.3% for the IMRT+C and the IMRT alone arms, respectively. While more grade 3-4 acute toxicities were discovered for the IMRT+C arm (79.6% vs. 52.4%; p<0.001), rates of grade 3-4 late toxicities were similar (21.3% vs. 18.1%; p=0.56).

"Our next step is a Phase II-III trial in which we intend to compare disease control rates using reduced-dose radiation with cisplatin or nivolumab against the standard of care," added Dr. Yom.
-end-
This project was supported by grants U10CA180868 (NRG Oncology Operations), U10CA180822 (NRG Oncology SDMC), UG1CA189867 (NCORP), U24CA196067 (NRG Specimen Bank), U24CA180803 (IROC) from the National Cancer Institute (NCI).

Citation

Yom SS, Torres-Saavedra P, Caudell JJ, Waldron JN, Gillison ML, Xia P, Truong MT, Kong C, Jordan R, Subramaniam RM, Yao M, Chung CH, Geiger JL, Chan JW, O'Sullivan B, Blakaj DM, Mell LK, Thorstad WL, Jones CU, Banerjee RN, Lominska C, Le QT. Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002). J Clin Oncol. 2021 Jan 28:JCO2003128. doi: 10.1200/JCO.20.03128. Epub ahead of print. PMID: 33507809.

About NRG Oncology

NRG Oncology conducts practice-changing, multi-institutional clinical and translational research to improve the lives of patients with cancer. Founded in 2012, NRG Oncology is a Pennsylvania-based nonprofit corporation that integrates the research of the legacy National Surgical Adjuvant Breast and Bowel Project (NSABP), Radiation Therapy Oncology Group (RTOG), and Gynecologic Oncology Group (GOG) programs. The research network seeks to carry out clinical trials with emphases on gender-specific malignancies, including gynecologic, breast, and prostate cancers, and on localized or locally advanced cancers of all types. NRG Oncology's extensive research organization comprises multidisciplinary investigators, including medical oncologists, radiation oncologists, surgeons, physicists, pathologists, and statisticians, and encompasses more than 1,300 research sites located world-wide with predominance in the United States and Canada. NRG Oncology is supported primarily through grants from the National Cancer Institute (NCI) and is one of five research groups in the NCI's National Clinical Trials Network.

http://www.nrgoncology.org

NRG Oncology

Related Radiotherapy Articles from Brightsurf:

Genomic analysis predicts survival benefit of adjuvant chemotherapy following radiotherapy over radiotherapy alone in low-grade gliomas in NRG Oncology clinical trial
A practice-changing study, NRG Oncology clinical trial NRG-RTOG 9802, has demonstrated, for the first time, a survival benefit of adjuvant chemotherapy following radiotherapy over radiotherapy alone in certain subgroups of patients with high-risk, low-grade glioma (WHO classification: LGG, grade II), a type of brain tumor that originates from glial cells.

Outcomes in radiotherapy-treated patients with cancer during COVID-19
The delivery of radiotherapy in 209 patients with cancer during the COVID-19 outbreak in Wuhan, China, is evaluated in this case series.

Shorter radiotherapy treatment for bowel cancer patients during COVID-19
An international panel of cancer experts has recommended a one-week course of radiotherapy and delaying surgery as the best way to treat patients with bowel cancer during the COVID-19 pandemic.

The pros and cons of radiotherapy: Will it work for you?
Women undergoing radiotherapy for many cancers are more likely than men to be cured, but the side effects are more brutal, according to one of Australia's most experienced radiation oncology medical physicists.

How to keep boron inside cells during radiotherapy: a novel approach to cancer treatment
Boron neutron capture therapy (BNCT) is a technique in which p-boronophenylalanine (BPA) is transferred to cancer cells, and the boron in it undergoes nuclear fission reaction upon irradiation of thermal neutrons, releasing high energy particles that kill the cells.

Prolonged breath-holding could help radiotherapy treatment of cardiac arrhythmias
A technique that enables patients suffering from heart conditions to hold their breath safely for over five minutes could have potential as part of a new treatment for cardiac arrhythmias, say researchers at the University of Birmingham.

Zebrafish 'avatars' can help decide who should receive radiotherapy treatment
To date, there is no method for clearly determining whether radiotherapy will be an effective treatment for individual cancer patients.

One dose of radiotherapy as effective as five doses for cancer in the spine
A single dose of radiotherapy is as 'effective' as five doses for end-of-life cancer patients suffering with painful spinal canal compression, finds a large study conducted by UCL.

Personalized and powerful: UK to lead next-generation radiotherapy research
The UK will be transformed into a global hub for radiotherapy research, pioneering the use of the latest techniques such as FLASH radiotherapy and artificial intelligence, with a new £56 million research network announced by Cancer Research UK today.

Oxygen in hyperbaric chamber provides relief after radiotherapy
Hyperbaric oxygen therapy (HBOT) can relieve self-reported symptoms and side-effects of radiotherapy against cancer in the pelvic region, a study shows.

Read More: Radiotherapy News and Radiotherapy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.